{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:35:17Z","timestamp":1788014117699,"version":"build-2784847793"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"\n Importance<\/jats:title>\n Cutaneous malignant neoplasms are the most common subsequent neoplasm after blood or marrow transplant (BMT), but a full assessment among survivors is lacking.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To identify risk factors for subsequent cutaneous malignant neoplasms using the BMT Survivor Study (BMTSS).<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective cohort study included patients who underwent transplant from 1974 to 2014 at City of Hope, University of Minnesota, or University of Alabama at Birmingham and survived 2 years or longer, as well as a comparison cohort of siblings. Both groups completed the BMTSS survey. Data analysis took place from October 2022 to October 2024.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Demographics, pre-BMT and BMT-related therapeutic exposures, chronic graft-vs-host disease (cGVHD), and posttransplant immunosuppression.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Incident cutaneous malignant neoplasms (basal cell carcinoma [BCC], squamous cell carcinoma [SCC], and melanoma) after BMT. Exposures were evaluated for association with subsequent neoplasms using proportional subdistribution hazards models (reported as subdistribution hazard ratio [SHR] and 95% CI).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among the 3880 BMT survivors (median [range] age at BMT, 44.0 [0-78.0] years; 2165 [55.8%] male; 190 [4.9%] Black, 468 [12.1%] Hispanic, 2897 [74.7%] non-Hispanic White, and 325 [8.4%] of other race [including Asian and Pacific Islander] and multiracial) who were followed up for a median (range) of 9.5 (2.0-46.0) years, 605 developed 778 distinct cutaneous neoplasms (BCC, 321; SCC, 231; melanoma, 78; and unknown type, 148). The 30-year cumulative incidence of any cutaneous malignant neoplasm was 27.4% (BCC, 18.0%; SCC, 9.8%; and melanoma, 3.7%). Seventy-year cumulative probabilities of BCC, SCC, and melanoma were considerably higher in BMT survivors than siblings (18.1% vs 8.2%, 14.7% vs 4.2%, and 4.2% vs 2.4%, respectively). Among BMT survivors, risk factors for subsequent cutaneous malignant neoplasms included age of 50 years and older at BMT (BCC: SHR, 1.76; 95% CI, 1.36-2.29; SCC: SHR, 3.37; 95% CI, 2.41-4.72), male sex (BCC: SHR, 1.39; 95% CI, 1.10-1.75; SCC: SHR, 1.85; 95% CI, 1.39-2.45), pre-BMT monoclonal antibody exposure (BCC: SHR, 1.71; 95% CI, 1.27-2.31), allogeneic BMT with cGVHD (BCC: SHR, 1.48; 95% CI, 1.06-2.08; SCC: SHR, 2.61; 95% CI, 1.68-4.04 [reference: autologous BMT]), post-BMT immunosuppression (BCC: SHR, 1.63; 95% CI, 1.24-2.14; SCC: SHR, 1.48; 95% CI, 1.09-2.02; melanoma: SHR, 1.90; 95% CI, 1.16-3.12), and transplant at City of Hope (BCC: SHR, 3.55; 95% CI, 2.58-4.89; SCC: SHR, 3.57; 95% CI, 2.34-5.47 [reference: University of Minnesota]) or University of Alabama at Birmingham (BCC: SHR, 2.35; 95% CI, 1.35-4.23; SCC: SHR, 2.63; 95% CI, 1.36-5.08 [reference: University of Minnesota]). Race and ethnicity other than non-Hispanic White were protective for BCC (Black: no cases; Hispanic: SHR, 0.27; 95% CI, 0.16-0.44; other race and multiracial: SHR, 0.26; 95% CI, 0.14-0.50 [reference: non-Hispanic White]) and SCC (Black: SHR, 0.17; 95% CI, 0.04-0.67; Hispanic: SHR, 0.28; 95% CI, 0.16-0.50; other race and multiracial: SHR, 0.13; 95% CI, 0.05-0.37 [reference: non-Hispanic White]). Total body irradiation was associated with BCC risk among those younger than 50 years at BMT (SHR, 1.92; 95% CI, 1.27-2.92).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study, the high risk of cutaneous malignant neoplasms and malignant-specific risk factors suggest a need for personalized patient counseling and posttransplant dermatologic surveillance.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2024.5129","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T11:01:00Z","timestamp":1734519660000},"page":"265","source":"Crossref","is-referenced-by-count":6,"title":["Incidence of and Risk Factors for Cutaneous Malignant Neoplasms After Blood or Marrow Transplant"],"prefix":"10.1001","volume":"161","author":[{"given":"Kristy K.","family":"Broman","sequence":"first","affiliation":[{"name":"University of Alabama at Birmingham, Birmingham"},{"name":"Birmingham VA Medical Center, US Department of Veterans Affairs, Birmingham, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingrui","family":"Meng","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Holmqvist","sequence":"additional","affiliation":[{"name":"Childhood Cancer Center, Skane University Hospital, Department of Clinical Sciences, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Balas","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Richman","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Landier","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Hageman","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Ross","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alysia","family":"Bosworth","sequence":"additional","affiliation":[{"name":"City of Hope, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hok Sreng","family":"Te","sequence":"additional","affiliation":[{"name":"University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britany","family":"Hollenquest","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Lennie","family":"Wong","sequence":"additional","affiliation":[{"name":"City of Hope, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Bhatia","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Forman","sequence":"additional","affiliation":[{"name":"City of Hope, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saro H.","family":"Armenian","sequence":"additional","affiliation":[{"name":"City of Hope, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Weisdorf","sequence":"additional","affiliation":[{"name":"University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita","family":"Bhatia","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"13","key":"doi240061r1","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1056\/NEJM199703273361301","article-title":"Solid cancers after bone marrow transplantation.","volume":"336","author":"Curtis","year":"1997","journal-title":"N Engl J Med"},{"issue":"5","key":"doi240061r2","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1182\/blood-2008-05-158782","article-title":"Solid cancers after allogeneic hematopoietic cell transplantation.","volume":"113","author":"Rizzo","year":"2009","journal-title":"Blood"},{"issue":"7","key":"doi240061r3","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1001\/jamadermatol.2015.121","article-title":"Cutaneous malignant neoplasms in hematopoietic cell transplant recipients: a systematic review.","volume":"151","author":"DePry","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"2","key":"doi240061r4","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1200\/JCO.2000.18.2.348","article-title":"New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia.","volume":"18","author":"Soci\u00e9","year":"2000","journal-title":"J Clin Oncol"},{"issue":"2","key":"doi240061r5","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1200\/JCO.2001.19.2.464","article-title":"Solid cancers after bone marrow transplantation.","volume":"19","author":"Bhatia","year":"2001","journal-title":"J Clin Oncol"},{"issue":"25","key":"doi240061r6","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.20.00231","article-title":"Total body irradiation and risk of breast cancer after blood or marrow transplantation: a Blood or Marrow Transplantation Survivor Study report.","volume":"38","author":"McDonald","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"doi240061r7","doi-asserted-by":"publisher","first-page":"738","DOI":"10.7326\/0003-4819-131-10-199911160-00004","article-title":"Malignant neoplasms in long-term survivors of bone marrow transplantation.","volume":"131","author":"Kolb","year":"1999","journal-title":"Ann Intern Med"},{"issue":"31","key":"doi240061r8","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.1200\/JCO.2015.60.9487","article-title":"Risk of subsequent neoplasms during the fifth and sixth decades of life in the Childhood Cancer Survivor Study cohort.","volume":"33","author":"Turcotte","year":"2015","journal-title":"J Clin Oncol"},{"issue":"34","key":"doi240061r9","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1200\/JCO.19.00129","article-title":"Chemotherapy and risk of subsequent malignant neoplasms in the Childhood Cancer Survivor Study cohort.","volume":"37","author":"Turcotte","year":"2019","journal-title":"J Clin Oncol"},{"issue":"8","key":"doi240061r10","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/j.jid.2021.01.018","article-title":"Incidence and risk factors for de novo cutaneous squamous cell carcinoma in a contemporary cohort of long-term hematopoietic cell transplantation survivors.","volume":"141","author":"Berano Teh","year":"2021","journal-title":"J Invest Dermatol"},{"issue":"11","key":"doi240061r12","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1016\/j.bbmt.2017.07.024","article-title":"Ascertainment of unmet needs and participation in health maintenance and screening of adult hematopoietic cell transplantation survivors followed in a formal survivorship program.","volume":"23","author":"Hahn","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"doi240061r13","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1111\/tri.13493","article-title":"Predicting skin cancer in organ transplant recipients: development of the SUNTRAC screening tool using data from a multicenter cohort study.","volume":"32","author":"Jambusaria-Pahlajani","year":"2019","journal-title":"Transpl Int"},{"issue":"14","key":"doi240061r14","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/jnci\/djq238","article-title":"Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study.","volume":"102","author":"Friedman","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"doi240061r15","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1200\/JCO.2005.02.7052","article-title":"Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation.","volume":"24","author":"Leisenring","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"doi240061r16","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1186\/s12935-021-02325-9","article-title":"Risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systemic review and meta-analysis.","volume":"21","author":"Liu","year":"2021","journal-title":"Cancer Cell Int"},{"issue":"2","key":"doi240061r17","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jamadermatol.2015.3029","article-title":"Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer.","volume":"152","author":"Scott","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"2","key":"doi240061r18","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14171","article-title":"The incidence of post-transplant malignancies in kidney transplant recipients treated with rituximab.","volume":"35","author":"Bachelet","year":"2021","journal-title":"Clin Transplant"},{"issue":"2","key":"doi240061r19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1667\/RR1469.1","article-title":"Basal cell skin cancer after total-body irradiation and hematopoietic cell transplantation.","volume":"171","author":"Schwartz","year":"2009","journal-title":"Radiat Res"},{"issue":"2","key":"doi240061r20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1001\/jamadermatol.2015.3902","article-title":"Skin cancer risk in hematopoietic stem-cell transplant recipients compared with background population and renal transplant recipients: a population-based cohort study.","volume":"152","author":"Omland","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"5","key":"doi240061r21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1667\/RR13494.1","article-title":"Skin cancer incidence among atomic bomb survivors from 1958 to 1996.","volume":"181","author":"Sugiyama","year":"2014","journal-title":"Radiat Res"},{"issue":"10","key":"doi240061r22","doi-asserted-by":"publisher","first-page":"3802","DOI":"10.1182\/blood-2004-09-3411","article-title":"Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study.","volume":"105","author":"Curtis","year":"2005","journal-title":"Blood"},{"issue":"20","key":"doi240061r23","doi-asserted-by":"publisher","first-page":"4992","DOI":"10.1182\/blood-2008-09-178046","article-title":"Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"6","key":"doi240061r24","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.3390\/curroncol30060430","article-title":"Systematic review of calcineurin inhibitors and incidence of skin malignancies after kidney transplantation in adult patients: a study of 309,551 cases.","volume":"30","author":"Kulbat","year":"2023","journal-title":"Curr Oncol"},{"issue":"1","key":"doi240061r25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1001\/jamadermatol.2019.3353","article-title":"Age-specific incidence of melanoma in the United States.","volume":"156","author":"Paulson","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"5","key":"doi240061r27","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1001\/jamapediatrics.2019.6074","article-title":"Associations between race\/ethnicity and US childhood and adolescent cancer survival by treatment amenability.","volume":"174","author":"Delavar","year":"2020","journal-title":"JAMA Pediatr"},{"issue":"11","key":"doi240061r28","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1001\/jamadermatol.2020.2571","article-title":"Association of age, sex, race, and geographic region with variation of the ratio of basal cell to cutaneous squamous cell carcinomas in the United States.","volume":"156","author":"Lukowiak","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"9","key":"doi240061r29","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1158\/1055-9965.EPI-16-0280","article-title":"Absence of basal cell carcinoma in irradiated childhood cancer survivors of Black race: a report from the St. Jude Lifetime Cohort Study.","volume":"25","author":"Ehrhardt","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"5","key":"doi240061r30","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1016\/j.jaad.2011.04.037","article-title":"Melanoma surveillance in the United States: overview of methods.","volume":"65","author":"Watson","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"doi240061r31","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/904393","article-title":"Reporting melanoma: a nationwide surveillance of state cancer registries.","volume":"2015","author":"Raji","year":"2015","journal-title":"J Skin Cancer"},{"key":"doi240061r32","first-page":"55S","article-title":"Melanoma registry underreporting in the Veterans Health Administration.","volume":"33","author":"Dougall","year":"2016","journal-title":"Fed Pract"},{"issue":"11","key":"doi240061r33","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1097\/DSS.0000000000001561","article-title":"Melanoma reporting practices of United States dermatologists.","volume":"44","author":"Svoboda","year":"2018","journal-title":"Dermatol Surg"},{"key":"doi240061r11","unstructured":"SEER*Stat software. National Cancer Institute. Accessed November 11, 2024. https:\/\/seer.cancer.gov\/seerstat"},{"key":"doi240061r26","unstructured":"SEER*Explorer. National Cancer Institute. Accessed December 8, 2023. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2827593\/jamadermatology_broman_2024_oi_240061_1741115880.09108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T12:05:05Z","timestamp":1742385905000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2827593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2024.5129","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,1]]}}}